Pencor Adverse Reactions

Note: A "first-dose orthostatic hypotensive reaction" sometimes occurs with the initial dose of Doxazosin, especially when the patient is in the upright position. Syncope or other postural symptoms such as dizziness may occur. Subsequent occurrence with dosage increases is also possible. Incidence appears to be dose-related; thus it is important that therapy be initiated with the 1 mg dose.
Patients who are volume-depleted or sodium-restricted may be more sensitive to the orthostatic hypotension effects of Doxazosin, and the effect may be exaggerated after exercise.
Hypotensive side effects are more likely to occur in geriatric patients.
The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where applicable) - not necessarily inclusive: Those indicating need for medical attention: Incidence less frequent: Dizziness; Vertigo (dizziness or lightheadedness).
Incidence less frequent: Arrhythmias (irregular hearbeat); Dyspnea (shortness of breath); Orthostatic hypotension (dizziness or lightheadednss when getting up from a lying or sitting position; sudden fainting); Palpitations (pounding heartbeat); Peripheral edema (swelling of feet or lower legs); Tachycardia (fast heartbeat).
Incidence rare: Priapism (painful or prolonged erection of the penis).
Those indicating need for medical attention only if they continue or are bothersome: Incidence more frequent: Headache; Unusual tiredness.
Incidence less frequent: Nausea; Nervousness, restlessness, or unusual irritability; Rhinitis (runny nose); Somnolence (sleepiness or unusual drowsiness).
Benign Prostatic Hyperplasia: The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients. The incidence rates are based on combined data from seven placebo-controlled trials involving once daily administration of Pencor (Doxazosin mesylate) in doses of 1-16 mg in hypertensives and 0.5-8 mg in normotensives. The adverse events when the incidence in the Pencor group was at least 1%. No significant difference in the incidence of adverse events compared to placebo was seen except for dizziness, fatigue, hypotension, edema and dyspnea. Dizzines and dyspnea appeared to be dose-related.